NCT02740283
Unknown
Not Applicable
The Early Diagnosis of Gestational Diabetes Mellitus Study
First Affiliated Hospital, Sun Yat-Sen University0 sites300 target enrollmentMay 2016
ConditionsGestational Diabetes Mellitus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Gestational Diabetes Mellitus
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Enrollment
- 300
- Primary Endpoint
- Rate of GDM diagnosed in 18-20 gestational week.
- Last Updated
- 10 years ago
Overview
Brief Summary
The main purpose of the study is to evaluate an OGTT at 18 to 20 gestational weeks as an early diagnosis method of GDM in low risk pregnant women. By investigating maternal and neonatal outcomes that are associated with the early OGTT and regular OGTT results, the study will provide a evidence for the most appropriate time to perform an OGTT in pregnant women.
Investigators
Bin Liu
Dr.
First Affiliated Hospital, Sun Yat-Sen University
Eligibility Criteria
Inclusion Criteria
- •Singleton pregnant women will be invited to participate in this study if they are between 18 and 40 years of age, and have had their first prenatal visit in our center before 18 weeks 0 days of gestation.
Exclusion Criteria
- •Previous history of GDM or preexisting DM
- •Family history of diabetes mellitus (first degree relative with diabetes or a sister with GDM)
- •Body mass index\>30 kg/m2
- •Previous macrosomia (baby with birth weight \>4,000 g) or a history of stillbirth
- •Polycystic ovary syndrome
- •Medications: corticosteroids, antipsychotics
- •Participant not willing to take OGTT twice (at 18-20 gestational weeks and 24-28 gestational weeks), or not willing to have a series of prenatal care visits and deliver in our center.
Outcomes
Primary Outcomes
Rate of GDM diagnosed in 18-20 gestational week.
Time Frame: up to 12 months
Similar Trials
Terminated
Phase 2
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)Glioblastoma MultiformeGliosarcomaNCT01186406Duke University41
Completed
Phase 1
GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)Diabetes Mellitus, Type 1NCT02352974Johnny Ludvigsson12
Recruiting
Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesNCT05669430GV20 Therapeutics268
Terminated
Phase 1
A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNon-small Cell Lung CancerGastric CarcinomaGastroesophageal Junction CarcinomaClassical Hodgkin LymphomaDiffuse Large B-cell LymphomaPeripheral T-cell LymphomaCutaneous MelanomaHead and Neck Squamous Cell CarcinomaBladder CancerOvarian CancerTriple Negative Breast CancerCervical CancerNCT04254107Seagen Inc.133
Terminated
Phase 1
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT02335944Novartis Pharmaceuticals177